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ABSTRACT
Introduction: Infective endocarditis (IE) is among the
most serious infectious diseases in the western world.
Treatment requires lengthy hospitalisation, high-dosage
antibiotic therapy and possible valve replacement surgery.
Despite advances in treatment, the 1-year mortality
remains at 20–40%. Studies indicate that patients
experience persisting physical symptoms, diminished
quality of life and difficulties returning to work up to a
year postdischarge. No studies investigating the effects of
rehabilitation have been published. We present the
rationale and design of the CopenHeartIE trial, which
investigates the effect of comprehensive cardiac
rehabilitation versus usual care for patients treated for IE.
Methods and analysis: We will conduct a
randomised clinical trial to investigate the effects of
comprehensive cardiac rehabilitation versus usual care
on the physical and psychosocial functioning of
patients treated for IE. The trial is a multicentre, parallel
design trial with 1 : 1 individual randomisation to either
the intervention or control group. The intervention
consists of five psychoeducational consultations
provided by specialised nurses and a 12-week exercise
training programme. The primary outcome is mental
health (MH) measured by the standardised Short Form
36 (SF-36). The secondary outcome is peak oxygen
uptake measured by the bicycle ergospirometry test.
Furthermore, a number of exploratory analyses will be
performed. Based on sample size calculation, 150
patients treated for left-sided (native or prosthetic
valve) or cardiac device endocarditis will be included in
the trial. A qualitative and a survey-based
complementary study will be undertaken, to investigate
postdischarge experiences of the patients. A qualitative
postintervention study will explore rehabilitation
participation experiences.
Ethics and dissemination: The study complies with
the Declaration of Helsinki and was approved by the
regional research ethics committee (no H-1-2011-129)
and the Danish Data Protection Agency (no 2007-58-
0015). Study findings will be disseminated widely
through peer-reviewed publications and conference
presentations.
Registration: Clinicaltrials.gov identifier: NCT01512615.
ARTICLE SUMMARY
Article focus
▪ The CopenHeartIE trial is a randomised clinical
trial investigating the effects of comprehensive
cardiac rehabilitation versus usual care for
patients treated for infective endocarditis (IE).
▪ The hypothesis is that comprehensive cardiac
rehabilitation improves mental health (MH) and
physical capacity.
▪ Using a mixed method approach, a broad range
of outcome measures is collected to evaluate the
intervention.
Key messages
▪ Infective endocarditis (IE) is a life-threatening
disease. Patients experience severe decondition-
ing and diminished quality of life postdischarge.
▪ Studies exploring the effects of rehabilitation of
patients treated for IE have not been published.
▪ This trial is the first to examine physical functioning
(PF) and to test a comprehensive rehabilitation pro-
gramme on a large population of patients treated
for IE. CopenHeartIE will provide much-needed evi-
dence and insight into the postdischarge status
and rehabilitation needs of patients treated for IE.
Strengths and limitations of this study
▪ The study has been designed to meet the criteria
for high quality in non-pharmacological randomised
clinical trials with central randomisation, multicentre
participation, blinded assessment and analysis.
▪ We are aware of the subjective nature of the
mental-health component subscale (primary
outcome). Accordingly, we will interpret the find-
ings conservatively.
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BACKGROUND
Infective endocarditis (IE) is an infection of the heart
valves and/or adjacent structures. The bacteria may
invade and destroy the tissue, and vegetations can dis-
lodge into circulation and cause harmful and potentially
deadly complications. Despite improvements in diagnos-
tic tools, novel antibiotics and changes in treatment regi-
mens, the mortality of IE remains high.1–3 The
incidence of IE in the developed countries is currently
between 1.9 and 10.0 per 100 000 people/year,3 4 and is
rising due to the increase in degenerative valvular
disease in the elderly, increasing insertions of prosthetic
valves and implantable cardiac devices, and exposure to
invasive procedures and nosocomial bacteraemia.1 5–7
In Denmark, the incidence is at least 10 per 100 000
people/year, equivalent to approximately 500 patients/
year.4 The treatment includes a lengthy hospitalisation
with intravenous antibiotic therapy, extensive invasive
and non-invasive diagnostic procedures and, in about
50% of the patients, valve replacement surgery.4 The
in-hospital death rate of patients with IE is 10–25%,
between 20% and 40% at 1-year postdischarge and up to
50% at 10 years postdischarge.3 8–11 The causes of post-
discharge mortality are still poorly understood.
Health and quality of life
The disease, its treatments and the potential complica-
tions can lead to massive deconditioning of the
patients.12–15 The few existing studies on patient experi-
ences after discharge, indicate that patients treated for
IE have persisting physical and mental symptoms, such
as fatigue in 47% of patients,14 physical weakness in up
to 78% of patients14 15 and concentration problems and
memory loss in up to 35% of patients.14 Patients also
report diminished health-related quality of life,14 nega-
tively affected perceived health12 13 and up to 55%
experience anxiety and depression15 and 11% showed
signs of post-traumatic stress disorder.14 Furthermore,
35% of previously employed patients had not returned
to work after 12 months.14
Rehabilitation
Secondary prevention initiatives including cardiac
rehabilitation, is widely recommended by the European
Society of Cardiology (ESC).16 Although evidence of the
efﬁcacy is strong, cardiac rehabilitation is still poorly
implemented and often only on selected populations,
and thus the development of full comprehensive pre-
ventive programmes, according to the ESC, is war-
ranted.17 Studies exploring the effects of rehabilitation
of patients treated for IE are lacking. As there is no evi-
dence of the efﬁcacy, the provided rehabilitation is pre-
sumably often suboptimal or totally lacking. Lessons,
however, might be learned from rehabilitation studies in
patients with related cardiac conditions. The positive
effects of cardiac rehabilitation have been well docu-
mented, particularly in patients with coronary heart
disease (CHD) and heart failure (HF), where
rehabilitation has been proven to reduce hospital
re-admissions and mortality in a cost-effective way,18 19 as
well as improve quality of life.20 More speciﬁcally, studies
on the effect of exercise training have demonstrated an
increase in exercise capacity of up to 38% in patients
after valve replacement surgery21 and an increase in
peak VO2 of 2.3±2.2 (SD) ml/kg/min in the interven-
tion group compared with −0.3±2.1 (SD) ml/kg/min in
the control group as well as a signiﬁcant change in
quality of life in older patients with HF.22 Traditional
cardiac rehabilitation has focused on physical training
and standardised programmes, but studies indicate that
individualised content and supervised exercise compo-
nents are key design characteristics for improving out-
comes.23 In addition to exercise training, evidence
support interventions including patient education,
which in patients with CHD has been shown to improve
health-related quality of life and decrease healthcare
costs24 and psychological support, which has been
shown to improve psychological symptoms in patients
with CHD, such as depression and anxiety.25 Evidence
on the efﬁcacy of comprehensive interventions for
patients treated for IE, however, is needed. Based on the
effects of rehabilitation in other cardiac conditions, we
hypothesise that patients treated for IE can beneﬁt from
participating in a rehabilitation programme, consisting
of an individualised exercise training programme and a
psychoeducational intervention. Therefore, we have
designed the CopenHeartIE trial.
STUDY OBJECTIVES
The aim of the trial is to test a comprehensive cardiac
rehabilitation programme for patients treated for IE
versus usual care. The programme consists of a psychoe-
ducational component and an exercise-training compo-
nent. The primary hypothesis is that comprehensive
cardiac rehabilitation improves mental health (MH),
measured by the mental component scale (MCS) of the
Short Form 36 (SF-36) questionnaire, in patients treated
for IE with six points (13%) in the intervention group
compared with the control group after the completed
intervention. The estimated 13% increase in primary
outcome is based on a study on ICD recipients with a
comparable complex rehabilitation intervention which
found a similar increase (unpublished data from the
COPE-ICD trial26). The secondary hypothesis is that
physical capacity, measured as peak oxygen uptake
(VO2 peak) by the bicycle ergospirometry test, will be
3 ml/kg/min (20%) higher in the intervention group
compared with the control group after 12 weeks of exer-
cise training. Since no data on physical capacity exists on
patients treated for IE, this hypothesis is based on
rehabilitation studies including patients after heart valve
surgery.27 28 Exploratory analyses will test the hypotheses
that comprehensive cardiac rehabilitation improves
self-rated health, quality of life, nutritional status, sleep
quality and body image and reduces anxiety, depression
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and fatigue after 6, 12 and 24 months. Furthermore, we
intend to assess whether comprehensive cardiac rehabili-
tation can reduce healthcare utilisation, work cessation
and mortality and increase cost effectiveness after
24 months.
DESIGN
The CopenHeartIE trial is part of the overall
CopenHeart project, which is designed to develop
evidence-based knowledge on rehabilitation among
patients with complex cardiac conditions.29 The
CopenHeartIE trial is a multicentre, multidisciplinary,
randomised clinical trial designed to examine the effects
of a comprehensive cardiac rehabilitation programme
compared with usual care for patients treated for IE. In
addition to this, the CopenHeartIE trial includes two
complementary studies, aimed at investigating the post-
discharge experiences and rehabilitation needs of
patients treated for IE, and a qualitative postintervention
study to explore the meaning of the CopenHeartIE
rehabilitation programme from the patient’s perspective.
Accordingly, the trial combines quantitative and qualita-
tive research methods. The premise of mixed methods
research is that the use of qualitative and quantitative
approaches in combination provides a better under-
standing of the research problems than either approach
alone, because different types of questions require differ-
ent types of data and that mixed methods research pro-
vides strengths that offset the weaknesses of both
qualitative and quantitative research.30 The methods are
integrated by applying the mixed method embedded
experimental design and include qualitative data to
develop the intervention and to examine the process
of the intervention and the results of the trial (see
ﬁgure 1).30 31 The rationale for this approach is that the
quantitative ﬁndings provide a general understanding of
the research problem through statistical results, and
qualitative ﬁndings reﬁne and explain the results by
exploring participants’ views in greater detail. Evaluation
using qualitative research methods is increasingly pro-
moted in evidence-based rehabilitation.32–35 Qualitative
research alongside randomised controlled trials can con-
tribute in several ways to the development and evalu-
ation of complex healthcare interventions and may be
particularly useful in evaluating interventions that
involve social and behavioural processes that are difﬁcult
to explore or capture using quantitative methods
alone.36 As patient participation is paramount to the efﬁ-
cacy of the rehabilitation,37 we ﬁnd it highly valuable to
include the patients’ perspective in the development
and evaluation of the intervention. This paper presents
the study protocol for the CopenHeartIE randomised
clinical trial. The complementary studies are brieﬂy
described in a separate section.
Study population and eligibility criteria
Consecutive patients treated for left-sided (native or
prosthetic valve) or cardiac device endocarditis at the
tertiary referral heart centres in Copenhagen, Denmark
(Rigshospitalet and Gentofte Hospital) will be screened
for inclusion and approached for study participation.
The patients aged 18 years or older, having completed
treatment for IE based on the Duke Criteria,38 speaking
and understanding Danish and providing written
informed consent will be considered eligible for partici-
pation. The patients unable to understand study instruc-
tions, with a cardiac ischaemic event within the past
6 months, who are pregnant or breastfeeding, with
reduced ability to follow the planned programme due
to, for example, substance abuse problems or other
somatic illness, with considerable illness in the musculo-
skeletal system or with physical disability which compli-
cates exercise training or patients whose physician advise
against participation, will be excluded.
Study procedure, randomisation and follow-up
Patients eligible for participation will be approached by
a nurse or a physician from the research group during
the expected last week of their treatment for IE. A brief
oral introduction is initially given together with written
information describing the study and implications for
the patient in detail. The patient is given ample time to
read the information and if necessary involve a relative
in the decision making. The enrolling nurse or phys-
ician will return within 2–3 days or at a planned time to
answer any questions the patient or their relative might
have. The patient should subsequently be able to
provide informed consent or reject participation. When
Figure 1 The CopenHeartIE study. Mixed method—embedded experimental model.
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the informed consent form is signed attained, baseline
data will be collected including the baseline question-
naire package, demographic variables and clinical char-
acteristics. After baseline data collection, central
randomisation is conducted by telephoning the trial
coordinating centre, Copenhagen Trial Unit (http://
www.ctu.dk/), for randomised allocation. The allocation
sequence will be computer-generated with varying block
sizes, blinded to investigators, randomising patients 1 : 1
to either the experimental intervention versus usual care.
Thus, neither investigators nor patients or relatives can
inﬂuence to which group the patients are allocated. The
patients will be stratiﬁed according to sex and the treating
heart centre. For both groups, the follow-up assessment
will take place at 1 month (T1), 4 months (T4), 6 months
(T6) and 12 months (T12) postdischarge and a register-
based follow-up assessment will be conducted at
24 months (T24; see ﬁgure 2). In the event of complica-
tions arising after study enrolment, cases will be handled
individually (see Intervention deviation section).
The patients answer questionnaires independently of the
researchers, and before randomisation. All questionnaires
are distributed electronically, thus data management is
handled independently from the researchers who interpret
data. All data entry is doubled and stored electronically in
a coded database, and in an independent spread sheet,
only accessible for the CopenHeart group.
Personal information about potential and enrolled
patients will be collected electronically and shared in a
database only accessible to those within the project
group responsible for patient recruitment, to protect
conﬁdentiality before, during and after the trial.
Experimental intervention group
Patients in the intervention group will follow the inte-
grated rehabilitation programme, consisting of a psy-
choeducational component and an exercise training
component as well as usual care (see below). The inter-
vention has been developed and tested in two clinical
trials; the DANREHAB trial including patients with
ischaemic heart disease and HF,39 and the COPE-ICD
trial including patients with an implantable cardioverter
deﬁbrillator.26 The blood work and clinical control
described for the control group (see below) are incorpo-
rated in the follow-up of the intervention group.
Psychoeducational component
The aim of the psychoeducational intervention is to
provide emotional support and improve coping skills
and illness appraisal in order for the patient to respond
Figure 2 Patient flow.
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appropriately to physical and psychological symptoms.
Education and information about the disease prepare
the patient for expected symptoms and sensations.
Dialogue and shared reﬂection facilitate strategies for
coping with symptoms and experiences associated with
the condition, for example, anxiety and fear. Cardiac
care nurses with speciﬁc training will perform the psy-
choeducational intervention. Some of the most com-
monly reported concerns of patients treated for IE, such
as fatigue, gastrointestinal function and concerns about
work life are outlined in an inspiration guide for the
nurses to address when and if relevant (see table 1).
Information given will also be based on national guide-
lines and standard treatment of patients with IE, and on
the ﬁndings of the qualitative study on postdischarge
experiences described in the complementary studies
section of this paper. The consultations focus on
managing life after IE by establishing a joint approach
to disease management and coping strategies, using a
holistic view. The psychoeducational intervention is
inspired by RR Parse’s Human Becoming Practice
Methodologies Three Dimensions.40 These are inter-
preted as (1) discuss and give meaning to the past,
present and future, (2) explore and discuss events and
possibilities and (3) move along with envisioned possibil-
ities. According to this theory, there are three ways of
changing health: creative imaging, that is to see, hear
and feel what a situation might be like if lived in a differ-
ent way, afﬁrming personal patterns and value priorities
and shedding light on paradoxes, that is, looking at the
incongruence in a situation and changing the view held
of something. The nurse is truly present in the process
through discussions, silent immersion and reﬂection.
The human becoming practise methodology was chosen
to apply a holistic patient approach, focusing on the
coping and transformation process of the individual
person. Furthermore, the method is extensively used in
the outpatient heart clinics at the heart centre at
Rigshospitalet, such as for patients with inherited heart
diseases and adults with congenital heart disease and
ﬁnally documented in the COPE-ICD trial.26 41 The
consultations take place in a quiet setting at the out-
patient clinic and will last for approximately 1 h. The
nurse is able to facilitate contact with or seek advice
from a physician if needed. The ﬁrst consultation will be
approximately 1 week after discharge, and then once
every 4–6 weeks, with a total of ﬁve consultations.
Consultations can be done by telephone, according to the
patient’s wishes. The primary investigator will attend the
consultations regularly to ensure protocol compliance.
Physical exercise training component
The main objective of the exercise training is to improve
the patient’s physical capacity and facilitate lifestyle/
behavioural changes, which will subsequently result in
physical and psychological health beneﬁts for the
patient. However, the exercise training programme is
also targeted at relieving the fear and uncertainty that
the patient may feel in relation to physical activity. The
intervention is based on the European guidelines for
physical training in cardiac rehabilitation16 and complies
with the recommendations on physical activity of the
Danish National Board of Health.42 The intervention
consists of three components (1) individual planning of
the exercise training, (2) 12 weeks of high-intensity exer-
cise training and (3) continuous moderate daily physical
exercise.
Individually planned physical exercise by a specialised
cardiac rehabilitation physiotherapist
Integrating detailed information regarding the speciﬁc
type of IE, comorbidities, hospitalisation, activities of
daily living (ADL) and level of physical activity prior to
IE, the physiotherapist conducts a patient consultation
of up to 30 min. The consultation is based on the initial
testing of the patient, including the cardiopulmonary
exercise testing, described in the outcome measures
section, a 6 min walk test and a ‘sit to stand’ test. For all
patients an individual training diary is prepared, and
all patients are instructed in the use of a HR monitor
integrated into Polar watches, provided by
Rigshospitalet. The HR monitor and diary is essential to
Table 1 Inspiration guide for nursing consultations/psychoeducational intervention
1 2 3 4 5
How have you been? What has happened since you were here last time? x x x x x
Discuss the events leading up to the diagnosis of IE. Experiences before and during hospital admission. x
Address present thoughts and questions. x x x x x
How did you having IE affect your life? Are there things/activities you avoid or feel you can’t do after having IE? x
Have you initiated exercise training? How is training going? x x x x
Discuss social network/family. How do they handle the situation? Has anything changed in your social
relationships?
x
Have you having IE affected your work situation?/had financial consequences? x
Have you had a changed view/perception of your body and its functions? x
How is your health in relation to, for example, fatigue, dyspnoea, pain, appetite, gastrointestinal function, sleep,
sexual functioning, other?
x x x
Information/recommendations in relation to discussed issues/problems. x x x x x
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ensure CopenHeart training protocol compliance and
are returned for data collection at the end of the exer-
cise training intervention.
Intensive exercise training programme
The initial training sessions take place in a physiotherapist-
supervised setting at the primary investigating hospital,
Rigshospitalet, to ensure the quality, intensity and safety of
training. Training is started 4 weeks postdischarge to
ensure optimum postsurgery healing after heart valve
surgery or cardiac device implantation. Using wireless elec-
trodes integrated into t-shirts (Corus-Fit, CardioCardio and
Corus Exercise Assistant, CEA, vs 2.0.16, Finland) potential
cardiac arrhythmias, electrocardiographic abnormalities
such as ST-depression, ST-elevation, Q-wave or T-wave
altering, atrial ﬁbrillation and ventricular arrhythmias and
training intensity level are monitored. After 1–3 exercise
training sessions at Rigshospitalet, the patient continues
the programme at a local CopenHeart certiﬁed training
facility supervised by physiotherapists or as supervised
home-based training. Supervised home-based exercise
training has shown similar results as hospital-based exercise
training,43 and has been conﬁrmed in a Danish setting.44
The physical exercise training continues for 12 weeks,
comprising 3 sessions weekly of 60 min, with a total of
36 sessions. The training protocol consists of aerobic
and anaerobic exercise to accommodate endurance and
muscle strength.
An exercise training session consists of 10 min warm
up, 20 min of bicycling, 20 min of resistance training
and 10 min stretching and cool-down period. Using
the results from the cardiopulmonary exercise test
performed prior to the initial training session, in com-
bination with the Borg scale measuring subjective
exhaustion, the aerobic exercise is performed with a
gradually increasing intensity throughout the exercise
intervention period, corresponding to 13–17 at the Borg
Scale and 50–80% of the maximum HR. The anaerobic
resistance training is initiated at 30–40% of one repeti-
tion maximum (RM) for the upper body, and 40–50%
of one RM for the lower body, with an increasing work
load during the training sessions. To achieve cardiovas-
cular adjustment and reduce the risk of malignant
cardiac arrhythmias and ischaemia, the training session
is initiated and terminated with a warm-up and a cool-
down period to gradually increase and decrease training
intensity and HR. This cardiovascular adjustment has
been proven to reduce the risk of ischaemia and
arrhythmia in relation to exercise training.45 46 Training
is predominantly performed in the upright position to
reduce left ventricle preload (diastolic volume) and the
risk of ischaemia and arrhythmias due to HF.46
Sustained moderate daily physical exercise
Participants are instructed to perform moderate physical
exercise at least 30 min/day during the intervention
period, for example, bicycling, walking, gardening,
jogging or recreational sports. Daily moderate physical
exercise is encouraged to be continued throughout life.
Intervention deviations
Both components of the intervention will be supervised
regularly by the primary investigator to ensure protocol
compliance. Modiﬁcation of the allocated intervention due
to surgery complications, rehospitalisation or emerging
comorbidities (eg, pneumonia, pericardial exudation and
musculoskeletal problems) will be individually assessed,
and the time of the primary outcome assessment at
4 months (described in section below) will be corrected in
accordance with changes in the intervention.
Usual care control group
Patients in the control group will follow standard follow-up
for patients treated for IE, with one to two visits within the
ﬁrst month postdischarge, including blood work and clin-
ical assessment. Haemoglobin level, infection variables,
kidney function and, on indication, liver status is assessed,
and blood cultures are drawn on suspicion of IE relapse.
Blood pressure, pulse and temperature parameters are
obtained. If results give cause for concern, the patient will
see a specialist physician during the follow-up visit. A trans-
thoracic echocardiogram will be performed within the ﬁrst
year postdischarge, typically between 1 and 6 months post-
discharge and again at 12 months, depending on whether
the individual patient has had heart valve surgery and on
the status of the native or replaced valve. These patients
will be contacted at 1, 4, 6, 12 and 24 months for outcome
assessment, including functional test, questionnaires and
clinical data collection (see ﬁgure 2).
Outcomes and data collection
Numerous data will be collected to evaluate the effect and
meaning of the intervention. The primary and the second-
ary outcome reﬂect the primary modiﬁable factors of the
intervention. Since almost no evidence exists, a number of
explorative outcomes will also be collected.
Primary outcome
MH will be measured by the Mental Component
Subscale (MCS) of the Medical Outcome Study Short
Form 36 (SF-36) questionnaire47 after 1 month (T1),
4 months (T4), 6 months (T6), 12 months (T12) and
24 months (T24). The SF-36 questionnaire is a measure
of self-rated health. It is a validated multipurpose health
survey comprised of 36 items that address the following
eight dimensions: physical functioning (PF), role phys-
ical (RP), bodily pain (BP), general health (GH), vitality
(VT), social functioning (SF), role emotional (RE) and
MH. The ﬁrst four scales (PF, RP, BP and GH) are then
combined into a physical component scale and the
latter four (VT, SF, RE and MH) into an MSC.47 The
instrument was chosen for its ability to detect changes
in self-rated health within domains that could potentially
be inﬂuenced by the CopenHeartIE intervention. MH
was chosen as the primary outcome as other studies
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have shown that MH is affected in patients with IE com-
pared to healthy controls13 14 and the rehabilitation
intervention focuses on this modiﬁable factor.
Secondary outcome
Physical capacity will be measured by peak VO2 using
cardiopulmonary exercise testing (Ergo-Spiro CS-200,
Schiller, Switzerland) by investigators blinded to the
intervention group. The test will be performed accord-
ing to current guidelines for ergospirometry testing,48–50
using an ergometer bicycle with spirometry, monitoring
heart rhythm, blood pressure, ECG and measuring gas
exchange during workload and in the following recovery
period. Average test duration is 10–15 min including
pretestand post-test phase without work load. Before
each session, calibration will be performed to address
changes in room temperature, humidity and air O2
content. A standardised ramp protocol will be used with
an initial work load of 25 or 50 W, increasing gradually
by 12.5 W/min until peak exhaustion. Peak exhaustion
is evaluated by a respiratory exchange ratio (RER)≥1.10
or subjective exhaustion of the patient. To encourage
patients equally, independent of the tester, a standar-
dised guide has been developed. During the test, clinical
manifestations, ECG abnormalities (ST depression, ST
elevation, q-wave and t-wave changes, supraventricular or
ventricular arrhythmias), blood pressure response and
several physiological parameters will be observed and
documented. The test will be performed by either a
cardiac care nurse or a physician. For safety reasons,
preset criteria for initiation and/or termination of the
test have been deﬁned. The test will be performed prior
to the exercise training programme (T1), after 12 weeks
of exercise training (T4) and at 12 months follow-up
(T12). Physical capacity was chosen as the secondary
outcome measure, as studies indicate that patients
treated for IE are physically deconditioned after long-
term illness and hospitalisation.14
Exploratory outcomes
A more extensive evaluation of the physical and psycho-
logical status of the patients over time will be performed,
exploring demographic, clinical, paraclinical and
imaging variables, as well as additional physical capacity
tests and additional questionnaires exploring, for
example, fatigue, sleep quality and anxiety and depres-
sion (see table 2).
Data collected from ofﬁcial national registers regard-
ing mortality, hospitalisation, emergency room visits,
outpatient visits, medication, employment status and
payment of welfare beneﬁts (sick leave payment and
early retirement pension) will be collected at 24 months
to assess the long-term effects of the intervention. The
Danish ofﬁcial national registers are well functioning
with a small percentage of lost data.64 Consequently, the
method is well suited as an outcome measure in small
patient populations. Data will be collected from the
Danish National Patient Register,65 the Danish National
Health Service Register,66 the Danish National
Prescription Registry,67 the Danish National Causes of
Death Register68 and registers on transfer payments and
labour market afﬁliation.69 70
Economic evaluation
An economic evaluation will be conducted alongside the
trial to assess the cost utility of comprehensive cardiac
rehabilitation compared with usual care in the study
population. The economic evaluation will compare the
costs to QALYs (quality-adjusted life years) and take a
societal perspective as recommended nationally. QALYs
and costs will be assessed at the end of the intervention,
6 months from randomisation and later after 24 months
from randomisation using register-based follow-up.
QALYs will be estimated using the self-completed
EQ-5D instrument, which is a standardised instrument
assessing ﬁve dimensions of self-reported health status
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression).71 72 The estimated calculations will
be evaluated using Danish preference weights.73
Information on costs will only include costs that are
expected to differ between the intervention and usual
care group.59 Included costs in the evaluation are health
costs associated with the rehabilitation programme,
other healthcare costs (healthcare utilisation apart from
rehabilitation), patient costs and costs of productivity
losses. Information on costs will be collected by a
mixture of activity-based costing, surveys, patient diaries
and by the use of registers.
Results from the analysis will be reported as an incre-
mental cost-effectiveness analysis (ICER). Sensitivity ana-
lysis will be conducted to express uncertainty in the
estimates.74 The reporting of ICER is presented using
Bayesian methods, including bootstrapping and pre-
sented as cost-effectiveness acceptability curves.75
Sample size, power calculations and interim analysis
We will perform a randomised trial with a continuous
response variable from independent control and inter-
vention group participants with one control per inter-
vention group participant. A previous study on an IE
population found that the MSC was normally distributed
with a SD of 13.13 If the true difference between the
intervention and control group means is six points, we
will need to include 75 participants in each study group
(a total of 150 participants) to be able to reject the null
hypothesis, stating that the mean in the intervention
and the control groups are the same with a power of
80%. The type I error probability associated with this
test of this null hypothesis is 5%.
For the secondary outcome, VO2, we will be able to
reject the null hypothesis that the population means of
the experimental and control groups are equal with a
probability (power) of 75.4%, assuming the VO2 is nor-
mally distributed with an SD of 6.9,27 28 and the true dif-
ference in the experimental and control means is 3 ml/
kg/min.
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A data monitoring and safety committee will be
informed, every 9 months, of all serious adverse events
occurring in the two study groups. An interim analysis
meeting will be held by the data monitoring and safety
committee to review data relating to intervention efﬁ-
cacy, participant safety and quality of trial conduct. The
committee will evaluate data on the primary and second-
ary outcome measures; MH (SF-36)/peak VO2 (efﬁcacy)
and all serious adverse events (safety/tolerability). After
the interim analysis meeting, the committee will make a
recommendation to the steering committee whether to
continue, hold or terminate the trial. This recommenda-
tion will be based primarily on safety and efﬁcacy consid-
erations and will be guided by statistical monitoring
guidelines deﬁned by the trial safety charter.
Statistical analysis
Data will be pseudoanonymised and analysed, blinded
by a trial-independent statistician using intention-to-treat
analyses and a mixed model with repeated measures
(MMRM) for continuous outcome measures.76 Using
MMRM ensures that missing data values (in the case of
the primary and secondary outcome) will not create bias
as long as the missing values are random. Two-sided tests
will be performed. The level of signiﬁcance is set at 5%.
Dealing with multiplicity, gate keeping will be used to
adjust the observed p values for primary and secondary
outcomes.77 Both original and adjusted p values will be
reported.
For the primary and secondary outcomes, we will
conduct sensitivity analysis to assess the potential impact
of non-random missing values. For each intervention
group (A and B) some quantities (imputing quantities)
will be computed to be used to impute missing values in
a group (A or B) as explained below. A comparison
between groups A and B where missing values in group
A are imputed using imputing quantities obtained from
group A and missing values from group B are imputed
using imputing quantities obtained from group B is
referred to as a best-case analysis. If missing values in
group A are imputed using imputing quantities obtained
from group B and vice versa the comparison is called a
Table 2 CopenHeartIE—exploratory quantities subjected to post hoc analysis
Quantity Time of measure
Type of
quantity
Demographic
Sex Baseline Binary (M/F)
Age, height, weight Baseline Continuous
Marital, occupational, educational status Baseline Categorical
Clinical
NYHA classification Baseline, 1, 4, 12 Continuous
Previous heart disease, diabetes mellitus, kidney disease, chronic obstructive
pulmonary disease (COPD), comorbidities, hypertension, dyslipidaemia, smoking
Baseline Binary (Y/N)
Medication Baseline, 1, 4, 12 Binary (Y/N)
BMI, nutritional screening Baseline, 1, 4, 12 Continuous
Endocarditis-specific data:
Valve/device affected, type of surgery due to IE Baseline Categorical
Cerebral insult ±, haemodialysis ± Baseline Binary (Y/N)
Length of hospitalisation (days), weight loss related to IE (kg) Baseline Continuous
Paraclinical and imaging
Blood work(haemoglobin, infection-, kidney, liver and selected nutritional
parameters, electrolytes, cholesterol and thyroid status, ProBNP)
Baseline, 1, 4, 12 Continuous
Echocardiogram Baseline, 4, 12 Continuous
Physical function
6 min walking test51 Baseline, 1, 4, 12 Continuous
Sit to stand test52 1, 4, 12 Continuous
Questionnaires
Physical activity level53 BL, 1, 4, 6, 12, 24 Binary (Y/N)
SF-3647 HADS,54 QoL-CV55 BL, 1, 4, 6, 12, 24 Continuous
Emotions and Health56 BL Continuous
Rehabilitation57 12 Continuous
HeartQoL R,58 EQ-5D59 BL, 6, 12, 24 Continuous
IPAQ60 1, 4, 12, 24 Continuous
MFI-2061 BL, 1, 4, 12 Continuous
PSQI62 1, 6 Continuous
BIQLI63 BL, 6 Continuous
BL, baseline; BMI, body mass index;EQ-5D, EuroQoL; HADS, Hospital Anxiety and Depression Scale; HeartQoL R, Heart-Related Quality of
Life; IPAQ, International Physical Activity Questionnaire; MFI-20, Multidimensional Fatigue Inventory; PSQI, Pittsburgh sleep quality index;
QoL-CV, quality of life - cardiac version; SF-36, Short Form 36; BIQLI, body image quality of life inventory.
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worst-case analysis. The imputed quantities for the
primary outcome would be the group mean at T1
(X1-bar), the group mean at T4 (X4-bar), the group
mean at T6 (X6-bar), the mean difference between the
value measured at T4 and that measured at T1 (delta 1),
and the mean difference between the value measured at
T6 and that measured at T4 (delta-2). Table 3 explains
how the quantities will be used to impute missing values
in a group (either the same group or the other interven-
tion group).
If the SE of a parameter estimate calculated using
imputed data is smaller than that of the corresponding
parameter calculated using complete case data it will be
replaced by the latter SE when the p value is calculated.
Long-term register-based outcomes will be analysed by
two different models: non-negative count outcomes (eg,
number of contacts to the hospital or number of visits to
general practitioners) will be analysed by a Poisson
model or a zero-inﬂated Poisson model if the number of
zeros are large, and time-to-event data (eg, cause-speciﬁc
mortality and leaving the labour market) will be ana-
lysed with survival methods (Kaplan-Meier estimator and
Cox regression model). Especially for socio-economic
outcomes, competing risk due to mortality will be con-
sidered if a large proportion of patients die during
follow-up.
Explorative data will be analysed using appropriate stat-
istical methods according to type of data (see table 2).
SPSS V.19.0 and SAS V.9.3 will be used.
COMPLEMENTARY STUDIES
Qualitative study on postdischarge experiences
The postdischarge experiences of patients treated
for IE will be explored through semistructured quali-
tative interviews, which take a phenomenological−her-
meneutic approach. The data derived from this study
will be used to address relevant issues designing the
rehabilitation intervention. The patients treated for IE,
3–6 months postdischarge will be identiﬁed through hos-
pital admission lists. A sample sufﬁcient to achieve data
saturation will be included. The study aims to answer the
following thematic research questions: What are the
experiences of returning home after treatment for IE?
What are the new experiences, if any, in daily living?
Which health problems, if any, have patients experi-
enced? What are the concerns, if any, for the future?
The data analysis is inspired by Ricoeur’s theory of inter-
pretation and consists of three levels: naive reading,
structured analysis and critical interpretation and discus-
sion. Qualiﬁed interviewees will be chosen, ensuring a
representative sample in relation to sex, age and
surgery/non-surgery.
Survey-based study
The postdischarge status of the patients treated for IE
will be explored through a national survey. The standar-
dised questionnaires SF-36,47 78–81 Hospital Anxiety and
Depression Scale (HADS),54 Multidimensional Fatigue
Inventory (MFI-20),61 82 EuroQoL—EQ-5D,59 83 Heart-
Related Quality of Life (HeartQoL R),58 International
Physical Activity Questionnaire (IPAQ)60 84 and a ques-
tionnaire developed by the Danish Heart Foundation on
the extent and quality of rehabilitation offered will be
sent out to patients who have undergone treatment for
IE, 6–12 months postdischarge. The instruments are all
validated and have good reliability and responsive-
ness.54 58 60 61 83 85 The data will provide knowledge on
patients’ self-rated health, quality of life, fatigue, anxiety
and depression, body image and extent and quality of
the rehabilitation currently received. The patients will
be identiﬁed through the National Patient Register65
and questionnaires will be sent out to 210 of them. We
aim to achieve a response rate of 70%, using repeat
mailing strategies and/or telephone reminders to maxi-
mise response if necessary.86 This should result in an
Table 3 Statistical appendix
Observed pattern in group
B at the times (T1, T4, T6)
Imputed value in group
B at T1
Imputed value in group
B at T4
Imputed value in group
B at T6
mis*, mis, mis X1-bar† X4-bar‡ X6-bar§
mis, mis, Y3¶ Y3—(delta1**+delta2††)‡‡ Y3—delta2
mis, Y2, mis Y2—delta1 Y2+delta2
Y1, mis, mis Y1+delta1 Y1+delta1+delta2
Y1, Y2, mis Y2+delta2
Y1, mis, Y3 (Y1+delta1+Y3—delta2)/2
mis, Y2, Y3 Y2—delta1
The use of imputed quantities derived from observed values in a group (group A) to impute missing values in a group (group B).
*The value at T4 is missing in group B.
†Mean of values observed in group A at time T1.
‡Mean of values observed in group A at time T4.
§Mean of values observed in group A at time T6.
¶Observed value in group B at time T6.
**The mean of difference between value observed at time T4 and observed at time T1 in group A.
††The mean of difference between value observed at time T6 and observed at time T1 in group A.
‡‡If an inputed value is <0 it is set equal to 0.
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estimated 150 questionnaire respondents. Data will be
anonymised and analysed by relevant descriptive statis-
tical methods.
Qualitative study on rehabilitation participation
experiences
After the intervention, an interview study, including 10%
of the intervention population or until data saturation
has been reached, will be conducted, to explore the
experiences and processes behind the potential effect of
the intervention. The study aims to answer the following
thematic research questions: What are the experiences
of participating in the integrated rehabilitation pro-
gramme? Which components of the programme are
meaningful? In what way? Participant selection and
applied methods in this study are consistent with that of
the qualitative study on postdischarge experiences.
ETHICS
The trial has been approved by the Regional Research
Ethics Committee (no H-1-2011-129) and the Danish Data
Protection Agency (no 2007-58-0015). All eligible patients
will be informed about the trial verbally and in writing,
and the patients are included after written informed
consent is obtained. All data will be handled conﬁdentially
and patients are ensured anonymity. The study complies
with the latest Declaration of Helsinki and is registered at
ClinicalTrials.gov (NCT01512615). An independent safety
committee comprised of an international group of experts
is monitoring the trial; ensuring good clinical practise stan-
dards are being upheld. No serious risks are anticipated to
receiving rehabilitation. No risks have previously been
reported in relation to psycho-educational consultations.
The physical exercise training and the cardiopulmonary
exercise testing will be supervised by competent health-
care professionals and will be in accordance with current
guidelines on safety when testing and training cardiac
patients.87 88 Efforts will be made to avoid arrhythmias
during workload testing and exercise training by protocol
with a cool-down period, which positively affects serious
complications. Staff members will be trained according to
guidelines to handle cardiac arrest or other disease-
speciﬁc or device-speciﬁc emergencies. All serious and
moderate adverse events will be registered and reported
according to the protocol.
Not providing rehabilitation to the control group can
be ethically justiﬁed, as current national and inter-
national guidelines give no speciﬁc recommendations
on cardiac rehabilitation for patients treated for IE. The
scope and quality of rehabilitation offered to this popu-
lation is unknown, but suspicions are, that often no or
suboptimal rehabilitation is provided. The survey-based
complementary study, described previously in this paper,
will hopefully provide more insight. In screening
patients for participation, the enrolling nurse or phys-
ician will exclude patients with a compelling rehabilita-
tion need, for instance after a cerebral embolic event.
Furthermore, patients are informed of the study design
before giving their consent, and are free to decline
participation.
DISCUSSION
This randomised clinical trial is the ﬁrst to examine PF by
cardiopulmonary exercise testing and to test a comprehen-
sive rehabilitation programme on a large heterogeneous
population of patients treated for IE. CopenHeartIE will
provide much-needed evidence and insight on the post-
discharge status and rehabilitation needs of patients
treated for IE for healthcare professionals and policy-
makers to make qualiﬁed, evidence-based decisions in
everyday clinical practise and as a foundation for national
and international guidelines. With increased physical and
psychological well-being of patients, lower morbidity and
healthcare utilisation expected in case of a positive
outcome, patients and society are anticipated to beneﬁt
greatly. Whether it produces neutral, negative or positive
results, the CopenHeartIE trial will have implications for
clinical practise in follow-up care of patients treated for IE
in the western world.
The patients may decline participation due to an
unwillingness to return to hospital after a lengthy illness
and hospitalisation. We will attempt to avoid this problem
by informing patients of the potential beneﬁts of partici-
pation, for example, the security we provide by following
them closely after postdischarge and the value to science
of their participation for future patients. Furthermore, it
is documented that a substantial number of patients in
rehabilitation studies control group perform self-initiated
physical exercise training, possibly motivated by the study
information during the recruitment process.39 Hence, we
will abstain from giving extensive information about the
training programme, or elaborate on the health beneﬁts
of physical training before knowing to which group the
patient is randomised.
The study has been designed to meet the criteria for
high quality in non-pharmacological randomised clinical
trials89 with central randomisation, multicentre participa-
tion, blinded assessment of the exercise outcome,
blinded analysis by study independent statisticians and
furthermore, detailed information on the intervention
received and usual care will be collected, including infor-
mation on self-initiated exercise training during the trial
period. For the primary outcome, the mental-health com-
ponent subscale, we are aware of the subjective nature of
the data collected. Accordingly, we will interpret the ﬁnd-
ings conservatively.
Safety aspects and Data Monitoring Safety Committee
In supervised exercise training and testing of other
cardiac patient groups than patients after IE, the risk of
adverse effects is low (eg, ischaemic heart disease,
chronic HF); however, no current national safety instruc-
tions exist. Patient safety is given highest priority, and
exercise training after heart valve surgery is considered
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safe based on results from exercise testing and training
with HF patients.87 88 Any serious adverse events will be
registered as part of the data collection.
The Data Monitoring Safety Committee (DMSC)
works independently from the funder and has no com-
peting interests, and consists of two clinicians and a stat-
istician. The committee is responsible for safeguarding
the interests of trial participants, assessing the safety and
efﬁcacy of the interventions during the trial, and for
monitoring the overall conduct of the clinical trial. The
steering committee and the DMSC communicate regu-
larly and at least every 9 months the overall number of
all serious adverse events is reported.
Dissemination plan
The results of the trial and complementary studies will
be published in relevant international peer-reviewed
journals. Authorship will be determined according to
the guidelines of the International Committee of
Medical Journal Editors. Owing to the comprehensive-
ness of the outcome measures the results will be pre-
sented in more than one scientiﬁc paper as relevant.
Economic and long-term follow-up will be reported as
data become accessible.
Trajectory
Inclusion was initiated in December 2011 and is expected
to be completed at the end of 2013. Results from two of
the complementary studies are expected during 2012, and
from the clinical trial in 2014. To achieve adequate partici-
pant enrolment, patients are recruited from two independ-
ent heart centres, and another heart centre, already in
partnership of the trial, will be invited for inclusion if the
enrolment rate declines. The inclusion rate is carefully
monitored weekly. The patients in doubt are contacted
several times during hospitalisation, and if necessary after
hospital discharge by phone.
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